ReviewNeuropsychiatric disease and treatment2016
Suvorexant: a promising, novel treatment for insomnia.
Review in Neuropsychiatric disease and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Research Progress and Future Perspectives of Orexin Receptor Antagonists in Insomnia Therapy.Molecules (Basel, Switzerland) · 2026Review
- Efficacy and Safety Profile of Suvorexant for the Treatment of Insomnia.Current drug safety · 2026Review
- A new direction for adjunctive therapy of difficult-to-treat depression: examining the role of orexin receptor antagonists.European archives of psychiatry and clinical neuroscience · 2025Review
- Current Considerations in the Diagnosis and Treatment of Circadian Rhythm Sleep-Wake Disorders in Children.Seminars in pediatric neurology · 2023Article
- Article
- Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans.Pharmacology, biochemistry, and behavior · 2022Article
- Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies.Neuropsychiatric disease and treatment · 2021Review
- Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.Neuroscience bulletin · 2020Review
- Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study.PloS one · 2020Article
- Impact of Sleep Disorder as a Risk Factor for Dementia in Men and Women.Biomolecules & therapeutics · 2020Review
- Optogenetic activation of short neuropeptide F (sNPF) neurons induces sleep in Drosophila melanogaster.Physiology & behavior · 2019Article
- Investigation of New Orexin 2 Receptor Modulators UsingMolecules (Basel, Switzerland) · 2018Article
- Suvorexant for insomnia in older adults: a perspective review.Drugs in context · 2018Review
- Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.BMJ case reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.